2259884-03-0

Hazard Information

Questions And Answer

• clinical trial

  Mazdutide (IBI362 or LY3305677) is a synthetic peptide analogue of mammalian oxyntomodulin and a once-weekly GLP-1 and glucagon receptor dual agonist. In a 12-week multiple-ascending-dose phase 1b study in Chinese patients with type 2 diabetes (clinical trial reg. no. NCT04466904, clinicaltrials.gov), mean changes in HbA1c ranged from −1.46% to −2.23% with mazdutide (−1.98% with 1.5 mg dulaglutide and −0.87% with placebo). Mean changes in body weight were up to −5.4% with mazdutide, −0.9% with dulaglutide, and −1.1% with placebo. A 12- to 16-week phase 1b study in Western patients with type 2 diabetes (clinical trial reg. no. NCT03928379, clinicaltrials.gov) reported mean changes in HbA1c up to −2.16% with mazdutide (−0.70% with placebo) and mean changes in body weight up to −11.2 kg with mazdutide (−2.0 kg with placebo). In both studies, mazdutide was well tolerated, with gastrointestinal adverse events most frequently reported.;

Supplier